Post-Traumatic Headache

7
Pipeline Programs
5
Companies
7
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 4 programs with unclassified modality

On Market (2)

Approved therapies currently available

Amgen
AIMOVIGApproved
erenumab-aooe
Amgen
injection2018
Eli Lilly and Company
EMGALITYApproved
galcanezumab-gnlm
Eli Lilly and Company
injection2018

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
1
AIMOVIG(Erenumab)Phase 2Monoclonal Antibody3 trials
Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic HeadacheN/A1 trial
Active Trials
NCT04369729Completed101Est. Aug 2025
NCT04825678Completed240Est. Sep 2023
NCT04098250Completed6Est. Jan 2024
+1 more trials
Ipsen
IpsenChina - Tianjin
1 program
1
AbobotulinumtoxinAPhase 41 trial
Active Trials
NCT03928496Completed40Est. Feb 2017
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
Galcanezumab-GnlmPhase 41 trial
Active Trials
NCT06901518Completed25Est. Nov 2024
Genomics
GenomicsUK - Oxford
2 programs
1
ErenumabPhase 2Monoclonal Antibody
Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic HeadacheN/A
Teva
TevaIsrael - Petach Tikva
1 program
1
FremanezumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03347188Completed87Est. Jun 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenErenumab
Eli Lilly and CompanyGalcanezumab-Gnlm
IpsenAbobotulinumtoxinA
AmgenErenumab
AmgenErenumab
TevaFremanezumab
AmgenInvestigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Clinical Trials (7)

Total enrollment: 599 patients across 7 trials

NCT04825678AmgenErenumab

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Start: Jun 2021Est. completion: Sep 2023240 patients
Phase 4Completed
NCT06901518Eli Lilly and CompanyGalcanezumab-Gnlm

The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches

Start: Aug 2020Est. completion: Nov 202425 patients
Phase 4Completed
NCT03928496IpsenAbobotulinumtoxinA

Abobotulinumtoxina Efficacy in Post-Traumatic Headache

Start: Aug 2013Est. completion: Feb 201740 patients
Phase 4Completed
NCT04098250AmgenErenumab

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

Start: Jan 2021Est. completion: Jan 20246 patients
Phase 2Completed
NCT03974360AmgenErenumab

Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache

Start: Apr 2019Est. completion: Dec 2019100 patients
Phase 2Completed
NCT03347188TevaFremanezumab

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

Start: Dec 2017Est. completion: Jun 202087 patients
Phase 2Completed
NCT04369729AmgenInvestigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Start: Sep 2020Est. completion: Aug 2025101 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space